CSI Market
Sign In | Register

Dianthus Therapeutics Inc (DNTH) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access DNTH Annual Cash Flow →
Quarterly cash flow trends provide additional context on Dianthus Therapeutics Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-91.05
Depreciation & amortization0.07
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.51
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation22.50
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction-0.03
Investment Income Net Amortization Of Discount And Premium-
License Fees Paid In Common And Preferred Stock-
Operating Lease Right Of Use Asset Amortization Expense0.25
Unbilled Receivable From Related Party-
Increase Decrease In Unbilled Receivable From Related Party-
Accounts Payable Accrued Expenses And Operating Lease Liabilities4.59
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.05
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets5.53
Other Working Capital0.94
Other Noncash Income (Expense)0.00
Other net6.87
Payments for (Proceeds from) Other Operating Activities-23.24
Discontinued operations0.00
Net Cash flow from Operating Activities-77.84
Investing Activities
Capital Expenditures-0.19
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities192.05
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-804.35
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-612.49
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock14.98
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net734.81
Payments Of Preferred Stock Issuance Costs-
Proceeds From The Pre Closing Financing-
Cash Acquired In Connection With The Reverse Recapitalization-
Payment Of Reverse Recapitalization Transaction Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents23.02
Proceeds From Private Placement-
Payments Of Issuance Costs Public Offering-0.17
Proceeds From Issuance Of Common Stock Pursuant To A T M Offering Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities749.79
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-78.03
Total Cash Flow59.46
4 historic quarters locked

Sign in to unlock the full Dianthus Therapeutics Inc cash flow history.

Sign In Create Free Account

About Dianthus Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001690585-26-000034

Figures are derived from filed reports and may be restated. Historical data is subject to revision.